Reported Outcomes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Health Catalyst Acquires Oncology Platform Carevive

Health Catalyst has finalized its acquisition of Carevive Systems, an oncology-focused health technology company.

Health catalystWhat you should knowOncology care through dataTrial matchingPatient monitoringTreatment careCare deliveryProcess improvementReported outcomesRegistry data

Mika Health and Cancer Support Community Aim to Close Gaps in Mental Health Care with United States First AI-Enabled Precision Support Digital Therapeutic That is Free for Cancer Patients

Mika Health and Cancer Support Community Aim to Close Gaps in Mental Health Care with United States First AI-Enabled Precision Support Digital Therapeutic That is Free for Cancer Patients
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomGandolf finkeSally wernerAmerican society for clinical oncologyGilda clubDigital healthMental healthMika healthCancer support communityClinical researchCancer support community aimClose gapsMental health careUnited state firstTherapeutic that

Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,.

United statesStacy nartkerWildon farwellAmy reillyJohn coxExchange commissionDrug administrationMyotonic dystrophy health indexEuropean medicines agencyDyne therapeutics incDose dependentMean splicing correction across all patientsMuscle strengthTimed function testsReported outcomesMean unadjusted

Dyne Therapeutics Announces New Clinical Data from ACHIEVE

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - .

United statesAmy reillyJohn coxStacy nartkerWildon farwellExchange commissionDyne therapeutics incEuropean medicines agencyDrug administrationMyotonic dystrophy health indexDose dependentMean splicing correction across all patientsMuscle strengthTimed function testsReported outcomesMean unadjusted

EHA 2024 | Results from Five Studies of Ascentage Pharma s Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress

SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and.

United statesHong kongLu yuSikander ailawadhiAscentage pharmaYifan zhaiJunjie chenPrnewswire ascentage pharmaSouthern medical universityEuropean hematology associationChina national medical products administrationAscentage pharma group incUniversity of texas md anderson cancer centerDana farber cancer instituteMd anderson cancer centerMajor national